81069-39-8

Upstream product

• 1071-46-1 hydrogen ethyl malonate 
• 696-41-3 m-iodobenzaldehyde 
• 626-00-6 1,3-Diiodobenzene 
• 140-88-5 ethyl acrylate 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 41070-12-6 3-iodocinnamic acid 

Downstream Products

• 295800-87-2 3-ethoxycarbonyl-4-(3-iodophenyl)pyrrole 
• 745078-81-3 ethyl 5-(3-((2-(3-hydroxy-2-(methoxycarbonyl)phenoxy)ethyl)amino)phenyl)isoxazole-3-carboxylate 
• 295800-89-4 2-ethoxycarbonyl-3-(3-iodophenyl)-11-N-(tert-butoxycarbonyl)dipyrromethane 
• 1361214-41-6 C₂₅H₂₉IN₂O₃ 
• 1361214-40-5 (E)-3-(3-iodophenyl)acrylaldehyde 
• 1354566-03-2 AVN 576 
• 1361214-47-2 (R)-3-((2R,3S)-2-((E)-3-iodostyryl)-4-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)azetidin-1-yl)-4-oxo-4-(((R)-1-phenylethyl)amino)butanoic acid 
• 1361214-44-9 (R)-tert-butyl 3-((2R,3S)-2-((E)-3-iodostyryl)-4-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)azetidin-1-yl)-4-oxo-4-(((R)-1-phenylethyl)amino)butanoate 
• 745078-97-1 ethyl (1R,2R)-2-(3-iodophenyl)cyclopropanecarboxylate 
• 745078-70-0 (E)-3-(3-iodophenyl)prop-2-en-1-ol 

Relevant academic research and scientific papers

Dialkylzinc-mediated allylic polyfluoroarylation reaction

Abstract We present an allylic polyfluoroarylation reaction with broad substrate scope and excellent functional group tolerance, using organozinc reagents under mild conditions. A catalytic amount of triphenylphosphine oxide efficiently promotes iodine-zinc exchange reaction between polyfluoroaryl iodide and dimethylzinc, and the resulting phosphine oxide-activated polyfluoroarylzinc undergoes substitution reaction with allylic halides to afford the corresponding polyfluoroarylated products.

Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging

SRX246 is a potent, highly selective human vasopressin V1a antagonist that crosses the blood-brain barrier in rats. CNS penetration makes SRX246 an ideal candidate for potential radiolabeling and use in visualization and characterization of the role of th

Palladium supported on a polyionic resin as an efficient, ligand-free, and recyclable catalyst for Heck, Suzuki-Miyaura, and Sonogashira reactions

Polyionic Amberlite resin formate (ARF), derived from commercially available Amberlite resin chloride by simple rinsing with aqueous formic acid, could be soaked with palladium(0) from palladium salts, the formate counteranion being the reducing source. The resulting Amberlite resin formate supported with palladium(0), ARF-Pd, showed excellent catalytic activity in Heck, Suzuki-Miyaura, and Sonogashira couplings with a range of substrates. The catalyst may be recovered easily and quantitatively without leaching and recycled; it was tested for five runs without any significant loss of activity. Georg Thieme Verlag Stuttgart.

METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B

The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME

Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAF RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS

The invention relates to novel compounds corresponding to formula (I) below: and to the method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

Protein-tyrosine phosphatase inhibitors and uses thereof

The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.

Structural control of photoinduced energy transfer between adjacent and distant sites in multiporphyrin arrays

A family of diphenylethyne-linked porphyrin dimers and trimers has been prepared via a building block approach for studies of energy-transfer processes. The dimers contain Mg and Zn porphyrins (MgZnU); the trimers contain an additional free base porphyrin

Process for the preparation of alkenylbenzenecarboxylic acid derivatives and alkenylnaphthalenecarboxylic acid derivatives

Compounds of the formula I STR1 in which p, m, Z, R, R' and Y are as defined in claim 1, can be obtained in a simple and economical manner by a novel process which comprises reacting a halide of the formula STR2 with the corresponding acrylic acid derivative, in the presence of a base and of certain palladium catalysts, such as palladium acetate. The compounds (I), and functional derivatives prepared therefrom, are useful for the preparation of photocrosslinkable polymers, which can in particular be employed as (so-called) photoresists.